Zacks Research Downgrades Medpace (NASDAQ:MEDP) to Hold

Medpace (NASDAQ:MEDP) was downgraded by equities researchers at Zacks Research from a “strong-buy” rating to a “hold” rating in a research report issued to clients and investors on Monday,Zacks.com reports.

MEDP has been the topic of a number of other research reports. Mizuho set a $660.00 price target on shares of Medpace in a research note on Friday. Truist Financial set a $555.00 price objective on Medpace in a report on Monday, October 27th. Barclays upped their target price on Medpace from $485.00 to $525.00 and gave the company an “underweight” rating in a research report on Monday, December 15th. Wall Street Zen cut Medpace from a “buy” rating to a “hold” rating in a report on Saturday, December 20th. Finally, BMO Capital Markets began coverage on Medpace in a report on Thursday, November 13th. They issued a “market perform” rating and a $600.00 price objective on the stock. Two investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and four have given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Reduce” and a consensus price target of $491.27.

Medpace Trading Up 1.5%

MEDP stock opened at $608.43 on Monday. Medpace has a 1-year low of $250.05 and a 1-year high of $626.26. The business’s 50 day simple moving average is $581.43 and its 200 day simple moving average is $506.43. The firm has a market capitalization of $17.14 billion, a PE ratio of 42.55, a PEG ratio of 2.01 and a beta of 1.43.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Wednesday, October 22nd. The company reported $3.86 EPS for the quarter, beating the consensus estimate of $3.50 by $0.36. The firm had revenue of $659.90 million for the quarter, compared to the consensus estimate of $640.49 million. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The company’s quarterly revenue was up 23.7% on a year-over-year basis. During the same period in the previous year, the company earned $3.01 earnings per share. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. As a group, sell-side analysts predict that Medpace will post 12.29 EPS for the current fiscal year.

Insider Transactions at Medpace

In related news, CEO August J. Troendle sold 668 shares of the business’s stock in a transaction dated Wednesday, December 3rd. The stock was sold at an average price of $590.69, for a total value of $394,580.92. Following the completion of the transaction, the chief executive officer owned 646,184 shares of the company’s stock, valued at $381,694,426.96. The trade was a 0.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Susan E. Burwig sold 20,000 shares of the company’s stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $609.15, for a total transaction of $12,183,000.00. Following the sale, the vice president directly owned 27,500 shares of the company’s stock, valued at $16,751,625. This represents a 42.11% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 387,925 shares of company stock valued at $233,386,647. 20.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Quent Capital LLC bought a new position in shares of Medpace in the 3rd quarter valued at $25,000. Optiver Holding B.V. acquired a new position in Medpace during the third quarter worth about $27,000. Geneos Wealth Management Inc. lifted its holdings in shares of Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after acquiring an additional 37 shares during the last quarter. Quarry LP acquired a new stake in shares of Medpace in the 3rd quarter valued at approximately $35,000. Finally, Employees Retirement System of Texas bought a new stake in shares of Medpace during the 2nd quarter valued at approximately $36,000. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.